Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diflunisal. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACMSD | Q8TDX5 | 6/20 | 0.89 |
| ▸ | TTR | P02766 | 2/20 | 0.89 |
| ▸ | DHFR | P00374 | 2/20 | 0.89 |
| ▸ | CA1 | P00915 | 2/20 | 0.89 |
| ▸ | CA2 | P00918 | 2/20 | 0.89 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.89 |
| ▸ | MEN1 | O00255 | 1/20 | 0.89 |
| ▸ | USP2 | O75604 | 1/20 | 0.89 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.89 |
| ▸ | LMNA | P02545 | 1/20 | 0.89 |
| ▸ | ALB | P02768 | 1/20 | 0.89 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.89 |
| ▸ | HPGD | P15428 | 1/20 | 0.89 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.89 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.89 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.89 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.89 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.89 |
| ▸ | MCL1 | Q07820 | 7/20 | 0.48 |
| ▸ | HNF4A | P41235 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diflunisal SCHEMBL30509654 | 0.94 | ACMSD (1.00) | ACMSDTTRDHFRCA1CA2 | |
| Diflunisal SCHEMBL4337 | 0.94 | ACMSD (1.00) | ACMSDTTRDHFRCA1CA2 | |
| Diflunisal SCHEMBL3848363 | 0.94 | ACMSD (1.00) | ACMSDTTRDHFRCA1CA2 | |
| Diflunisal SCHEMBL29367380 | 0.94 | ACMSD (1.00) | ACMSDTTRDHFRCA1CA2 | |
| Diflunisal SCHEMBL28338853 | 0.93 | ACMSD (0.97) | ACMSDTTRDHFRCA1CA2 | |
| Diflunisal SCHEMBL20876816 | 0.93 | ACMSD (0.97) | ACMSDTTRDHFRCA1CA2 | |
| Diflunisal SCHEMBL1869144 | 0.93 | ACMSD (0.97) | ACMSDTTRDHFRCA1CA2 | |
| Diflunisal SCHEMBL11425421 | 0.93 | ACMSD (0.97) | ACMSDTTRDHFRCA1CA2 | |
| Diflunisal SCHEMBL28916416 | 0.93 | ACMSD (0.97) | ACMSDTTRDHFRCA1CA2 | |
| Diflunisal SCHEMBL28350701 | 0.90 | ACMSD (0.91) | ACMSDTTRDHFRCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040203012-A1 | Method of detecting and monitoring prostate and ovarian cancers | MOUNT SINAI HOSPITAL (CA) | 2004-10-14 | — | — | US | claimed |
| EP-1390756-A1 | METHOD OF DETECTING AND MONITORING PROSTATE AND OVARIAN CANCERS | MOUNT SINAI HOSPITAL (CA) | 2004-02-25 | — | — | EP | claimed |
| WO-2002097438-A1 | METHOD OF DETECTING AND MONITORING PROSTATE AND OVARIAN CANCERS | MOUNT SINAI HOSPITAL (CA) | 2002-12-05 | — | — | WO | claimed |
| WO-1998059073-A1 | METHOD FOR DETECTION OF BREAST CANCER | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 1998-12-30 | — | — | WO | claimed |
| EP-0883813-A1 | DETECTION OF PROSTATE-SPECIFIC ANTIGEN IN BREAST TUMORS AND SERUM | MDS Nordion Inc. (CA) | 1998-12-16 | — | — | EP | claimed |
| US-5723302-A | DETERMINING AMOUNT OF FREE PROSTATE-SPECIFIC ANTIGEN RELATIVE TO PROSTATE-SPECIFIC ANTIGEN-ANTICHYMOTRYPSIN COMPLEX IN SERUM SAMPLE | NORDION INTERNATIONAL INC. (CA) | 1998-03-03 | — | — | US | claimed |
| US-5688658-A | DIAGNOSIS OF BREAST CANCER, FLUOROIMMUNOASSAY WITH ENZYME AMPLIFICATION | NORDION INTERNATIONAL, INC. (CA) | 1997-11-18 | — | — | US | claimed |
| WO-1997032215-A1 | DETECTION OF PROSTATE-SPECIFIC ANTIGEN IN BREAST TUMORS AND SERUM | MDS NORDION INC. (CA) | 1997-09-04 | — | — | WO | claimed |
| EP-0698215-A1 | DETECTION OF PROSTATE-SPECIFIC ANTIGEN IN BREAST TUMORS | NORDION INTERNATIONAL, INC. (CA) | 1996-02-28 | — | — | EP | claimed |
| WO-1994027152-A1 | DETECTION OF PROSTATE-SPECIFIC ANTIGEN IN BREAST TUMORS | NORDION INTERNATIONAL INC. (CA) | 1994-11-24 | — | — | WO | claimed |
| US-10006921-B2 | Markers of the male urogenital tract | SINAI HEALTH SYSTEM (CA) | 2018-06-26 | — | — | US | disclosed |
| US-9863005-B2 | Endometrial phase or endometrial cancer biomarkers | WALFISH, PAUL (CA) | 2018-01-09 | — | — | US | disclosed |
| US-20170315125-A1 | Methods For The Diagnosis Or Prognosis of Breast Cancer | WALFISH PAUL (CA) | 2017-11-02 | — | — | US | disclosed |
| EP-2567235-B1 | METHOD FOR THE DIAGNOSIS OF EPITHELIAL CANCERS BY THE DETECTION OF EPICD POLYPEPTIDE | WALFISH PAUL (CA) | 2017-08-30 | — | — | EP | disclosed |
| US-20170138963-A1 | MARKERS OF THE MALE UROGENITAL TRACT | SINAI HEALTH SYS (CA) | 2017-05-18 | — | — | US | disclosed |
| US-5688658-A | DIAGNOSIS OF BREAST CANCER, FLUOROIMMUNOASSAY WITH ENZYME AMPLIFICATION | NORDION INTERNATIONAL, INC. (CA) | 1997-11-18 | — | — | US | disclosed |
| US-5679534-A | PRENATAL EVALUATION OF FETAL PHENOTYPIC AND/OR GENOTYPIC DISORDERS; CONCENTRATION; ACCURACY | DIAMANDIS ELEFTHERIOS P (CA) | 1997-10-21 | — | — | US | disclosed |
| WO-1997032215-A1 | DETECTION OF PROSTATE-SPECIFIC ANTIGEN IN BREAST TUMORS AND SERUM | MDS NORDION INC. (CA) | 1997-09-04 | — | — | WO | disclosed |
| EP-0698215-A1 | DETECTION OF PROSTATE-SPECIFIC ANTIGEN IN BREAST TUMORS | NORDION INTERNATIONAL, INC. (CA) | 1996-02-28 | — | — | EP | disclosed |
| WO-1994027152-A1 | DETECTION OF PROSTATE-SPECIFIC ANTIGEN IN BREAST TUMORS | NORDION INTERNATIONAL INC. (CA) | 1994-11-24 | — | — | WO | disclosed |